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Summary
Background Although a preventable and treatable disease, tuberculosis causes more than a million deaths each year. 
As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic 
by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and 
programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by 
drug resistance and HIV status for 195 countries and territories from 1990 to 2016.
Methods We analysed 15 943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of 
sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to 
tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case 
notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific 
mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a 
Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the 
Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total 
fertility rate.
Findings Globally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 
9·02 million (95% uncertainty interval [UI] 8·05–10·16) and the number of tuberculosis deaths was 1·21 million 
(1·16–1·27). Among HIV-positive individuals, the number of incident cases was 1·40 million (1·01–1·89) and the 
number of tuberculosis deaths was 0·24 million (0·16–0·31). Globally, among HIV-negative individuals the age-
standardised incidence of tuberculosis decreased annually at a slower rate (–1·3% [–1·5 to –1·2]) than mortality did 
(–4·5% [–5·0 to –4·1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change 
in annualised age-standardised incidence was –4·0% (–4·5 to –3·7) and mortality was –8·9% (–9·5 to –8·4). Several 
regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 
2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa 
(13·7 for incidence and 14·9 for mortality), and the lowest ratios were in high-income North America (0·4 for 
incidence) and Oceania (0·3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest 
observed-to-expected ratios (67·3 for incidence and 73·0 for mortality), and high-income North America had the 
lowest ratios (0·4 for incidence and 0·5 for mortality).
Interpretation If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to 
end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to 
tuberculosis diagnosis and care, by developing new tools, scaling up interventions to prevent risk factors for 
tuberculosis, and integrating control programmes for tuberculosis and HIV.
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Introduction
Although tuberculosis is a preventable and treatable 
disease, it is the cause of more than a million deaths each 
year.1,2 Tuberculosis was the leading cause of death from 
a single infectious pathogen in 2016.1 The ambitious 
Sustainable Development Goal (SDG) target 3 aims to 
end the tuberculosis epidemic by 2030, and numeri­
cal milestones (eg, annual reduction in global tuber­
culosis incidence of 10% by 2025) have been set to 
achieve this target.3 Robust assessment, monitoring, and 
evaluation of progress towards this SDG target are 
therefore crucial to inform policy and programme 
decision making.
Accurately assessing the tuberculosis burden over 
time is difficult because of the paucity of high­quality 
data from many low­income and middle­income coun­
tries.2 The completeness of vital registration data is 
gradually improving, but many countries still do not 
have good­quality vital registration systems.1 Notification 
data can be of use as a proxy for tuberculosis incidence 
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in countries with high­quality health and surveillance 
systems where under­reporting is minimal;4 however, in 
most low­income and middle­income countries, these 
data are prone to under­reporting and cannot be 
interpreted without additional information on case 
detection rate.4,5 To deal with the lack of high­quality data 
in these countries, various methods have been used to 
estimate tuberculosis incidence (eg, adjusting for under­
reporting in notification data by use of expert opinion 
case detection rates,4 back­calculating incidence from 
prevalence survey data by use of different assumptions 
of the average duration of disease,4 or using a statistical 
triangulation approach2,6). For the Global Burden of 
Diseases, Injury, and Risk Factors Study (GBD) 2015, we 
used a statistical triangulation approach that modelled 
tuberculosis incidence, prevalence, and mortality simul­
taneously to generate consistent estimates for these 
parameters.2
The burden of tuberculosis varies by several factors 
including age, sex, location, HIV status, and drug­resistance 
status. Therefore, these factors should be taken into 
account when investigating tuberculosis trends. Addi­
tionally, the burden of disease in many countries has 
shifted from communicable to non­communicable dis­
eases in line with sociodemographic development (the 
epidemiological transition).7–9 As such, comparing the 
observed tuberculosis burden to that expected on the basis 
of a country’s socio­demographic level could be useful for 
guiding investment in research and interventions.2 For 
example, countries with a lower tuberculosis burden than 
expected relative to their socio­demographic development 
could provide insight into successful programmatic 
strategies, and countries with a higher burden than 
expected might need to investigate the reasons why. 
GBD 20152 examined the difference between the observed 
and expected burden of tuberculosis but did not provide a 
detailed assessment by drug­resistance type and HIV 
status. For GBD 2016, we assessed the levels and trends in 
the fatal and non­fatal burden of tuberculosis by drug­
resistance type and HIV status from 1990 to 2016, for 
195 countries and territories. We also aimed to analyse the 
association between these burdens and the country or 
territory’s Socio­demographic Index (SDI),1,10–12 which is a 
composite indicator of income, education, and fertility rate.
Methods
Overview
GBD is a systematic, scientific effort to quantify the 
comparative magnitude of health loss due to diseases, 
injuries, and risk factors by age, sex, and location over 
time. The conceptual and analytical framework for GBD 
and detailed methods have been published elsewhere.1,11,13 
We describe here the methods we used for the analysis of 
the burden of tuberculosis for GBD 2016.
Selection of input data
The input data we used to model mortality due to 
tuberculosis among HIV­negative individuals included 
Research in context
Evidence before this study
Tuberculosis causes more than a million deaths each year and 
was the leading cause of death from a single infectious 
pathogen in 2016. The global burden of tuberculosis has 
been estimated by several groups, including the WHO Global 
Tuberculosis Programme and the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) 2015. Nevertheless, 
trends in the burden of drug-resistant tuberculosis by HIV 
status and how the observed burdens differ from the levels 
expected on the basis of sociodemographic development have 
not been comprehensively assessed. We searched PubMed with 
the search terms (“tuberculosis”[MeSH] AND “drug-sensitive” 
OR “drug-susceptible”) OR “tuberculosis, 
multidrug-resistant”[MeSH] AND (“burden” OR “estimates”) 
AND “trend”, with no language restrictions, for publications up 
to June 7, 2018. We identified ten studies that provided 
population-based time trends for the burden of 
multidrug-resistant tuberculosis (incidence, prevalence, or 
deaths). Of these studies, the most recent period assessed was 
1999–2013 in Lebanon. None of these studies assessed the 
trends in the burden of drug-susceptible or multidrug-resistant 
tuberculosis by HIV status and compared these burdens with 
those expected on the basis of a country’s socio-demographic 
position.
Added value of this study
We found that, although HIV infection and drug-resistant 
tuberculosis have become the main challenges to tuberculosis 
control efforts, more than three-quarters of incident cases of 
tuberculosis and deaths due to tuberculosis in 2016 were 
estimated to occur in HIV-negative individuals who were 
susceptible to first-line tuberculosis drugs. During the past 
decade, the global rate of decline for incidence of both 
drug-susceptible and multidrug-resistant tuberculosis was 
slower than the corresponding rate of decline for mortality, for 
HIV-positive and HIV-negative individuals alike. Many countries 
had higher burdens of drug-susceptible or multidrug-resistant 
tuberculosis than expected on the basis of their level of 
socio-demographic development.
Implications of all the available evidence
If current trends in tuberculosis incidence continue, few 
countries will meet the Sustainable Development Goal target to 
end the tuberculosis epidemic by 2030. The pace of progress 
needs to be increased through interventions including 
improving the quality of and access to tuberculosis diagnosis 
and care, and integrating control programmes for tuberculosis 
and HIV.
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15 943 site­years of vital registration data, 1710 site­years 
of verbal autopsy data, 764 site­years of sample­based 
vital registration data, and 361 site­years of mortality 
surveillance data. We assessed and improved the quality 
and comparability of data on cause of death through 
multiple steps,12 including redistribution of garbage 
codes to underlying causes of death using GBD 
algorithms and adjusting for misclassified HIV deaths 
(ie, deaths caused by HIV being assigned to other 
underlying causes of death, such as tuberculosis, because 
of stigma or misdiagnosis). GBD 20161 also assessed the 
overall quality of data for each country (on the basis of 
completeness, garbage coding, detail of cause list, and 
time periods covered), and assigned a quality score from 
zero stars (lowest) to five stars (highest); a score of four to 
five is considered high quality (quality scores by country 
are in the appendix p 19). We removed verbal autopsy 
data for countries with a high prevalence of HIV (using 
an arbitrary cutoff value of 5% age­standardised pre­
valence of HIV), because verbal autopsy studies have a 
poor ability to distinguish deaths due to HIV from deaths 
due to tuberculosis among people who are HIV positive 
(HIV­tuberculosis deaths).2
Our input data for the estimation of mortality due to 
HIV­tuberculosis included 382 site­years of high­quality 
vital­registration data from countries where data on cause 
of death directly coded for HIV­tuberculosis and tuber­
culosis were available, and the number of tuberculosis 
cases (new and re­treatment) recorded as HIV­positive, 
and the number of tuberculosis cases (new and re­
treatment) with an HIV test result recorded in the WHO 
tuberculosis register.
In GBD 2016, we included multidrug­resistant tuber­
culosis (without extensive drug resistance) and ex­
tensively drug­resistant tuberculosis by HIV status as 
new outcomes (case definitions are in the appendix p 3). 
Input data included the number of cases of tuberculosis 
that were multidrug resistant, extensively drug resistant, 
had a drug­sensitivity testing result for isoniazid and 
rifampicin, and that were multidrug resistant with a 
drug­sensitivity result for second­line drugs from routine 
surveillance and surveys reported to WHO (for data 
availability by country see appendix p 16); relative risks of 
mortality for cases of tuberculosis that were multidrug 
resistant compared with cases that were drug susceptible, 
and relative risks for cases that were extensively drug 
resistant compared with multidrug resistant were 
extracted from studies identified via a systematic review 
(for details of systematic review see appendix p 37); and 
the risk of multidrug­resistant tuberculosis associated 
with HIV infection extracted from a meta­analysis.14
Our input data for modelling non­fatal tuberculosis 
included annual case notification data, data from pre­
valence surveys of tuberculosis, data from population­
based tuberculin surveys, and estimated cause­specific 
mortality rates of tuberculosis among individuals who 
were HIV positive and HIV negative. Links to data 
sources and code we used in analyses are in the appendix 
(pp 40–41).
Fatal tuberculosis
We modelled tuberculosis mortality among people who 
are HIV negative using the Cause of Death Ensemble 
modelling (CODEm) strategy,15–18 which evaluates a large 
number of potential models that apply different functional 
forms (mixed­effects models and spatiotemporal Gaussian 
process regression models) to mortality or cause fractions 
with varying combinations of predictive covariates. These 
covariates included alcohol (L per capita), diabetes (fasting 
plasma glucose in mmol/L), education (years per capita), 
lag­distributed income (LDI), indoor air pollution, outdoor 
air pollution, population density (people per km²), smoking 
prevalence, SDI, the summary exposure variable scalar 
(which indicates exposure to risk factors associated with 
tuberculosis; appendix p 9), and four new covariates added 
for GBD 2016 (ie, prevalence of tuberculosis, prevalence of 
latent tuberculosis infection, proportion of adults who are 
underweight, and the Healthcare Access and Quality 
[HAQ] Index19). We then selected the ensemble of CODEm 
models that performed best on out­of­sample predict­
ive validity tests (appendix pp 20–23). We estimated 
HIV­tuberculosis mortality using a population­attributable 
fraction approach, like in GBD 20152 (detailed methods and 
equations are in the appendix pp 34–36).
To split tuberculosis deaths and HIV­tuberculosis deaths 
by drug­resistance type, we first estimated the proportions 
of tuberculosis cases that were multidrug resistant for all 
locations and years using a spatiotemporal Gaussian 
process regression. Second, we estimated the proportions of 
tuberculosis cases that were multidrug resistant by HIV 
status on the basis of the risk of multidrug­resistant 
tuberculosis associated with HIV from a meta­analysis by 
Mesfin and colleagues.14 Third, we used the estimated 
proportions of cases of tuberculosis that are multidrug 
resistant by HIV status and the relative risk of death in 
multidrug­resistant cases compared with drug­susceptible 
cases to calculate the fraction of tuberculosis deaths among 
HIV­negative individuals attributable to multidrug­resistant 
tuberculosis, and the fraction of HIV­tuberculosis deaths 
attributable to multidrug­resistant tuberculosis (detailed 
methods and equations are in the appendix pp 23–24, 
35–36). Finally, we applied the fraction of tuberculosis 
deaths attributable to multidrug­resistant tuberculosis to 
the number of tuberculosis deaths we estimated using 
CODEm, and the fraction of HIV­tuberculosis deaths 
attributable to multidrug­resistant tuberculosis to our 
estimated number of HIV­tuberculosis deaths, to generate 
the number of multidrug­resistant tuberculosis deaths by 
HIV status by location, year, age, and sex.
To distinguish extensively drug­resistant tuberculosis 
from multidrug­resistant tuberculosis, we aggregated 
the cases of extensively drug­resistant tuberculosis and 
multidrug­resistant tuberculosis (with drug­sensitivity 
testing for second­line drugs) up to the GBD super­region 
See Online for appendix
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level (for analytical purposes we grouped 21 GBD regions 
into seven super­regions:13 central Europe, eastern Europe 
and central Asia; high­income; Latin America and 
Caribbean; north Africa and Middle East; south Asia; 
southeast Asia, east Asia, and Oceania; and sub­Saharan 
Africa) and calculated the proportion of cases of extensively 
drug­resistant tuberculosis among the cases of multidrug­
resistant tuberculosis at the super­region level. We then 
used these proportions and the relative risk of mortality 
among people with extensively drug­resistant tuberculosis 
compared with those with multidrug­resistant tuberculosis 
to calculate the fraction of extensively drug­resistant 
tuberculosis deaths among all multidrug­resistant tuber­ 
culosis deaths at the super­region level (detailed methods 
and equations are in the appendix p 24). These fractions 
were then applied to the estimated number of multidrug­
resistant tuberculosis deaths and multidrug­resistant 
HIV­tuberculosis deaths in countries within the super­
regions to calculate the number of deaths due to 
extensively drug­resistant tuberculosis by HIV status by 
location, year, age, and sex.
We linearly extrapolated mortality for extensively drug­
resistant tuberculosis back from 2016 assuming mortality 
was zero in 1992, 1 year before extensively drug­resistant 
tuberculosis was first recorded in USA surveillance data 
in 1993.20 Next, we subtracted the number of deaths due to 
extensively drug­resistant tuberculosis from the number 
of deaths due to multidrug­resistant tuberculosis to 
generate the number of deaths due to multidrug­resistant 
tuberculosis (without extensive drug resistance) by loca­
tion, year, age, and sex.
Non-fatal tuberculosis
We made several improvements to the statistical trian­ 
gulation approach we used in GBD 20152 to model non­
fatal tuberculosis. First, we estimated the prevalence of 
latent tuberculosis infection by location, year, age, and sex 
using data from population­based tuberculin surveys and 
cohort studies that reported the risk of developing active 
tuberculosis disease as a function of indura tion size.11 Next, 
we divided the inputs on prevalence (from tuberculosis 
prevalence surveys in low­income and middle­income 
countries), incidence (notification data from countries 
with a rating of four or five stars and estimated incidence 
from countries with ratings of zero to three stars), and 
cause­specific mortality rate by the risk­weighted 
prevalence of latent tuberculosis infection to model 
tuberculosis among individuals at risk in each country. A 
detailed explanation of how we prepared each of these 
data sources is in the appendix (pp 6–10).
To generate initial estimates of incidence for countries 
with a rating of zero to three stars, we did a regres­
sion analysis using mortality­to­incidence ratios (logit 
transformed) from locations with a rating of four or 
five stars as input data, with SDI as a covariate. We 
calibrated the lowest end of the SDI scale with a datapoint 
from a community­based cohort study,21 which reported 
that 49·2% of people with untreated pulmonary 
tuberculosis had died at the end of a 5 year follow­up 
period, to predict mortality­to­incidence ratios as a function 
of SDI for all locations and years. We then used the 
predicted mortality­to­incidence ratios and estimates of 
cause­specific mortality to calculate the age­sex specific 
incidence input for modelling in DisMod­MR 2.1,22 the 
GBD Bayesian meta­regression tool. In locations where 
our estimated mortality­to­incidence ratios were greater 
than notification­based mortality­to­incidence ratios, we 
used the notification­based ratios to calculate the incidence 
input. We then generated a final incidence estimate that 
is consistent with prevalence data and cause­specific 
mortality estimates using a Bayesian meta­regression.
We used DisMod­MR 2.1 to simultaneously model age­
sex specific tuberculosis incidence, prevalence, and 
mortality among the population who are latently infected 
and generate consistent trends in all parameters. We then 
multiplied the DisMod­MR 2.1 outputs by the prevalence 
of latent tuberculosis infection to get population­level 
estimates of incidence and prevalence. To distinguish HIV­
tuberculosis from all forms of tuberculosis, we applied the 
proportion of cases of HIV­tuberculosis among all cases of 
tuberculosis (estimated from a mixed­effects regression 
using the adult HIV mortality rate covariate as in 
GBD 20152) to the number of incident and prevalent cases 
of tuberculosis. We then applied the estimated proportion 
of cases of tuberculosis that are multidrug resistant to our 
predicted number of cases of tuberculosis, and the 
estimated proportion of cases of HIV­tuberculosis with 
multidrug­resistant tuberculosis (as described earlier for 
fatal tuberculosis) to our predicted number of HIV­
tuberculosis cases, to generate the number of cases 
of multidrug­resistant tuberculosis by HIV status. To 
distinguish extensively drug­resistant tuberculosis from 
multidrug­resistant tuberculosis, we calculated the pro­
portions of cases of extensively drug­resistant tuber culosis 
among the cases of multidrug­resistant tuberculosis at 
the super­region level and applied these proportions to 
multidrug­resistant tuberculosis cases.
Similar to our estimation for fatal tuberculosis with 
extensive drug resistance, we linearly extrapolated the 
prevalence and incidence of extensively drug­resistant 
tuberculosis back from 2016, assuming incidence and 
prevalence were zero in 1992 and in earlier years. Finally, 
we subtracted the number of cases of extensively drug­
resistant tuberculosis from the number of cases of 
multidrug­resistant tuberculosis to generate the number 
of cases of multidrug­resistant tuberculosis (without 
extensive drug resistance) by location, year, age, and sex. 
We used the GBD world population age standard to 
calculate age­standardised rates.
SDI
SDI, initially developed for GBD 20159 and updated for 
GBD 2016,1,10,11 was calculated on the basis of the 
geometric mean of three indicators: income per capita, 
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average years of schooling, and total fertility rates. SDI 
scores were scaled from 0 (lowest income, lowest 
average years of schooling, highest fertility) to 1 (highest 
income, highest average years of schooling, lowest 
fertility), and each location was assigned an SDI score 
for each year. We estimated the average association 
between SDI and tuberculosis incidence and mortality 
using a Gaussian process regression, and we then used 
these associations to estimate expected values at each 
SDI level.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author 
had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Global burden of tuberculosis in 2016
Globally in 2016, among HIV­negative individuals, we 
estimated 9·02 million (95% uncertainty interval [UI] 
8·05–10·16; figure 1, table 1) incident cases of tuberculosis 
and 1·21 million (1·16–1·27) deaths due to tuberculosis 
(figure 1, table 2). Among HIV­positive individuals, we 
estimated 1·40 million (1·01–1·89; figure 1, appendix 
pp 75–87) incident cases of tuberculosis and 0·24 million 
(0·16–0·31) deaths due to tuberculosis (figure 1, appendix 
pp 88–100). Almost two­thirds of HIV­negative tuberculosis 
incident cases (59·6% [59·2–59·7]) and deaths (63·1% 
[62·4–63·6]) were in males (figure 2). Most incident cases 
(89·5% [87·9–91·0]) and deaths (64·3% [63·6–65·0]) were 
in people younger than 65 years for both sexes. Among 
HIV­positive individuals, 53·8% (52·4–54·9) of incident 
cases of tuberculosis and 56·9% (56·2–57·6) of deaths due 
to tuberculosis were in males (appendix p 46). Most 
Figure 1: Global tuberculosis incidence (A) and mortality (B) by drug-resistance type and HIV status, 1990–2016
Dark lines are estimates and shaded areas are 95% uncertainty intervals. HIV-tuberculosis=tuberculosis in individuals with HIV/AIDS. Multidrug-resistant 
tuberculosis=multidrug-resistant tuberculosis without extensive drug resistance.
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incident cases of HIV­tuberculosis (82·4% [82·2–82·5]) 
and deaths due to HIV­tuberculosis (73·7% [72·7–74·8]) 
were among people aged 20–54 years for both sexes 
(appendix p 46).
Globally in 2016, among HIV­negative individuals, we 
estimated that 0·30 million (95% UI 0·26–0·34) incident 
cases of tuberculosis were multidrug resistant (table 1) and 
0·10 million (0·08–0·11) deaths were due to multidrug­
resistant tuberculosis (table 2). In individ uals who are HIV 
positive, we estimated that 35 815 (23 524–51 741) incident 
cases of tuberculosis were multidrug­resistant (appendix 
pp 75–87) and 18 375 (11 208–27 747) deaths were due 
Drug-susceptible tuberculosis Multidrug-resistant tuberculosis Extensively drug-resistant 
tuberculosis
All HIV-negative tuberculosis
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16
Global 8 705 207 
(7 754 638 to 
9 817 655)
–1·8 
(–2·0 to 
–1·5)
–1·3 
(–1·5 to 
–1·1)
295 637 
(261 369 to 
335 586)
11·5 
(10·8 to 
12·3)
–2·1 
(–2·9 to 
–1·3)
18 452 
(16 087 to 
21 187)
43·9 
(43·1 to 
44·8)
7·9 
(6·6 to 
9·1)
9 019 296 
(8 051 800 to 
10 156 811)
–1·6 
(–1·8 to 
–1·3)
–1·3 
(–1·5 to 
–1·2)
High-income 122 022 
(107 600 to 
138 800)
–5·3 (–5·7 
to 
–5·0)
–2·6 
(–2·8 to 
–2·4)
1715 
(1352 to 
2225)
1·6 
(0·1 to 
3·0)
–3·2 
(–5·3 to 
–0·6)
216 
(170 to 
280)
29·7 (28·3 
to 
31·1)
4·4 
(2·3 to 
7·0)
123 952 
(109 362 to 
140 956)
–5·3 
(–5·6 to 
–5·0)
–2·6 
(–2·8 to 
–2·4)
High-income North 
America
12 179 
(11 023 to 
13 394)
–2·5 
(–3·3 to 
–1·7)
–2·2 
(–2·6 to 
–1·8)
139 
(124 to 
155)
–3·5 
(–4·4 to 
–2·6)
–2·2 
(–2·8 to 
–1·5)
17 
(16 to 
20)
20·4 
(19·6 to 
21·0)
5·5 
(4·8 to 
6·1)
12 335 
(11 163 to 
13 563)
–2·5 
(–3·3 to 
–1·7)
–2·2 
(–2·6 to 
–1·8)
Australasia 1396 
(1194 to 
1603)
–3·5 
(–4·3 to 
–2·6)
–1·5 
(–2·1 to 
–0·9)
27 
(12 to 
49)
6·5 
(–1·8 to 
14·5)
–0·2 
(–11·0 to 
11·3)
3 
(2 to 
6)
25·0 
(18·4 to 
30·6)
7·5 
(–3·4 to 
18·9)
1426 
(1228 to 
1640)
–3·4 
(–4·2 to 
–2·5)
–1·4 
(–2·0 to 
–0·9)
High-income Asia 
Pacific
69 366 
(61 928 to 
77 057)
–6·4 
(–6·8 to 
–6·1)
–3·1 
(–3·5 to 
–2·7)
872 
(627 to 
1210)
2·5 
(0·1 to 
4·8)
–5·2 
(–8·6 to 
–1·6)
110 
(79 to 
152)
36·7 
(34·8 to 
38·5)
2·5 
(–0·9 to 
6·0)
70 347 
(62 801 to 
78 134)
–6·4 
(–6·7 to 
–6·1)
–3·1 
(–3·5 to 
–2·7)
Western Europe 30 930 
(24 845 to 
38 614)
–3·6 
(–4·2 to 
–3·1)
–1·8 
(–2·2 to 
–1·4)
512 
(401 to 
656)
1·0 
(0·0 to 
2·2)
–0·8 
(–2·0 to 
0·4)
64 
(50 to 
83)
27·1 
(25·6 to 
28·5)
6·9 
(5·6 to 
8·1)
31 506 
(25 320 to 
39 267)
–3·6 
(–4·2 to 
–3·0)
–1·8 
(–2·2 to 
–1·4)
Southern Latin America 8152 
(6651 to 
9877)
–4·6 
(–5·3 to 
–3·9)
–0·9 
(–1·7 to 
–0·3)
165 
(39 to 
519)
8·3 
(0·2 to 
18·2)
–0·7 
(–15·2 to 
11·4)
21 
(5 to 
65)
31·6 
(26·4 to 
35·8)
7·0 
(–7·6 to 
19·1)
8338 
(6857 to 
10 068)
–4·4 
(–5·2 to 
–3·8)
–0·9 
(–1·6 to 
–0·3)
Central Europe, 
eastern Europe, and 
central Asia
190 982 
(167 765 to 
218 563)
0·4 (0 to 
0·8)
–3·3 
(–3·9 to 
–2·7)
34 818 
(27 860 to 
42 503)
14·2 (11·2 
to 
17·5)
–2·3 
(–5·0 to 
0·2)
7629 
(6104 to 
9312)
55·4 (54·1 
to 
56·7)
9·0 
(6·2 to 
11·5)
233 428 
(206 001 to 
263 867)
1·3 (0·9 to 
1·7)
–2·9 
(–3·2 to 
–2·6)
Eastern Europe 102 960 
(88 487 to 
119 678)
1·3 
(0·7 to 
1·8)
–3·1 
(–3·9 to 
–2·3)
20 668 
(15 832 to 
26 250)
10·9 
(7·7 to 
14·4)
–1·1 
(–4·2 to 
1·6)
4529 
(3469 to 
5752)
55·3 
(53·9 to 
56·8)
10·1 
(7·1 to 
12·9)
128 157 
(110 861 to 
146 360)
2·1 
(1·5 to 
2·6)
–2·5 
(–3·0 to 
–2·1)
Central Europe 26 337 
(23 435 to 
29 369)
–1·4 
(–1·9 to 
–1·0)
–3·8 
(–4·1 to 
–3·4)
440 
(252 to 
757)
7·6 
(1·0 to 
14·2)
–5·1 
(–12·9 to 
2·6)
97 
(55 to 
166)
37·5 
(33·7 to 
41·1)
6·2 
(–1·6 to 
13·8)
26 873 
(23 937 to 
29 909)
–1·3 
(–1·8 to 
–0·9)
–3·8 
(–4·1 to 
–3·5)
Central Asia 61 685 
(53 120 to 
71 399)
–0·7 
(–1·3 to 
–0·2)
–4·1 
(–5·3 to 
–2·8)
13 709 
(10 092 to 
18 011)
31·6 
(24·9 to 
38·6)
–4·5 
(–9·2 to 
0·1)
3004 
(2211 to 
3947)
61·0 
(58·9 to 
63·0)
6·7 
(2·1 to 
11·4)
78 397 
(69 544 to 
88 584)
0·7 
(0·4 to 
1·0)
–3·9 
(–4·2 to 
–3·7)
Latin America and 
Caribbean
161 862 
(140 835 to 
184 477)
–3·2 (–3·5 
to 
–3·0)
–2·3 
(–2·5 to 
–2·1)
3491 
(2856 to 
4329)
10·3 (7·1 to 
14·0)
–3·3 
(–5·0 to 
–1·5)
276 
(226 to 
342)
34·5 (33·3 
to 
35·8)
6·5 
(4·8 to 
8·3)
165 629 
(143 934 to 
188 555)
–3·1 
(–3·4 to 
–2·8)
–2·3 
(–2·5 to 
–2·1)
Central Latin America 48 806 
(41 842 to 
56 204)
–2·4 
(–2·7 to 
–2·2)
–1·8 
(–2·0 to 
–1·5)
991 
(776 to 
1261)
17·5 
(15·7 to 
19·3)
–2·9 
(–4·8 to 
–1·0)
78 
(61 to 
100)
31·8 
(30·5 to 
33·1)
6·9 
(5·0 to 
8·8)
49 875 
(42 743 to 
57 514)
–2·3 
(–2·5 to 
–2·1)
–1·8 
(–2·0 to 
–1·6)
Andean Latin America 31 412 
(27 884 to 
35 278)
–6·0 
(–6·3 to 
–5·7)
–3·8 
(–4·3 to 
–3·4)
1417 
(1007 to 
2070)
6·3 
(2·0 to 
11·3)
–3·7 
(–7·6 to 
–0·1)
112 
(80 to 
163)
43·4 
(41·3 to 
45·6)
6·0 
(2·2 to 
9·7)
32 940 
(29 161 to 
36 850)
–5·8 
(–6·0 to 
–5·5)
–3·8 
(–4·2 to 
–3·4)
Caribbean 16 519 
(13 885 to 
19 541)
–3·0 
(–3·7 to 
–2·5)
–0·9 
(–1·6 to 
–0·2)
94 
(30 to 
277)
2·7 
(–5·2 to 
10·6)
–3·7 
(–13·8 to 
7·9)
7 
(2 to 
22)
27·9 
(20·8 to 
33·6)
6·1 
(–4·0 to 
17·7)
16 620 
(13 957 to 
19 656)
–3·0 
(–3·7 to 
–2·4)
–1·0 
(–1·6 to 
–0·2)
Tropical Latin America 65 126 
(56 191 to 
74 662)
–1·8 
(–2·3 to 
–1·3)
–2·2 
(–2·4 to 
–2·0)
989 
(832 to 
1150)
22·8 
(22·1 to 
23·5)
–3·2 
(–3·9 to 
–2·5)
78 
(66 to 
91)
32·5 
(31·5 to 
33·4)
6·6 
(5·9 to 
7·3)
66 193 
(57 040 to 
75 915)
–1·7 
(–2·2 to 
–1·2)
–2·2 
(–2·4 to 
–2·0)
(Table 1 continues on next page)
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to multidrug­resist ant tuberculosis (appendix pp 88–100). 
Among HIV­negative individuals in 2016, we estimated 
18 452 (16 087–21 187) incident cases of tuberculosis were 
extensively drug resistant and 10 920 (8896–13 162) deaths 
were due to extensively drug­resistant tuber culosis 
(tables 1 and 2). Among HIV­positive individuals in 2016, 
we estimated that 1303 (793–2019) incident cases of tuber­ 
culosis were extensively drug resistant and 1151 (689–1802) 
deaths were due to extensively drug­resistant tuberculosis 
(appendix pp 75–100). Estim ated tuberculosis prevalence by 
drug­resistance type and HIV status are available online.
Changes in the burden of tuberculosis over time
Globally, the annualised rate of change in age­standardised 
incidence of tuberculosis among HIV­negative individuals 
was –1·3% (95% UI –1·5 to –1·2) from 2006 to 2016 
(table 1), which is a slower rate of change than in 
1990–2006 (–1·6% [–1·8 to –1·3]; table 1). These rates of 
change are small compared with the decrease in the 
annualised rate of change in age­standardised 
tuberculosis mortality (–4·5% [–5·0 to –4·1]) from 2006 
to 2016, which is larger than the annualised rate of change 
from the period 1990–2006 (–3·2% [–3·7 to –2·9]; table 2).
Globally, the annualised rate of change in age­stan­ 
dardised incidence of tuberculosis among HIV­positive 
individuals decreased from 2006 to 2016 (–4·0% [95% UI 
–4·5 to –3·7]), whereas in 1990–2006 the rate of change 
increased (8·1% [7·5–8·8]; appendix pp 75–87). Mortality 
among HIV­positive individuals has decreased, with an 
annualised rate of change of –8·9% (–9·5 to –8·4) for 
Drug-susceptible tuberculosis Multidrug-resistant tuberculosis Extensively drug-resistant 
tuberculosis
All HIV-negative tuberculosis
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
Number of 
incident 
cases, 2016
Annualised rate of 
change of 
age-standardised 
incidence
1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16
(Continued from previous page)
Southeast Asia, east Asia, 
and Oceania
2 381 270 
(2 144 141 to 
2 637 352)
–3·6 (–3·9 
to 
–3·3)
–1·9 
(–2·1 to 
–1·8)
71 140 
(59 963 to 
86 643)
5·9 
(4·8 to 
6·9)
–4·0 
(–5·9 to 
–1·8)
6487 
(5468 to 
7900)
45·0 (44·1 
to 
46·0)
7·9 
(6·0 to 
10·1)
2 458 896 
(2 215 080 to 
2 722 674)
–3·4 
(–3·7 to 
–3·2)
–2·0 
(–2·2 to 
–1·8)
East Asia 1 207 570 
(1 136 842 to 
1 285 280)
–4·1 
(–4·2 to 
–3·9)
–2·0 
(–2·2 to 
–1·8)
50 864 
(44 680 to 
58 560)
4·8 
(3·9 to 
5·7)
–4·2 
(–5·4 to 
–2·9)
4638 
(4074 to 
5339)
45·1 
(44·3 to 
45·9)
7·7 
(6·6 to 
9·0)
1 263 072 
(1 188 367 to 
1 344 259)
–3·8 
(–4·0 to 
–3·6)
–2·1 
(–2·3 to 
–1·9)
Southeast Asia 1 161 747 
(993 911 to 
1 345 961)
–3·3 
(–3·9 to 
–2·9)
–2·2 
(–2·5 to 
–2·0)
19 831 
(12 086 to 
32 586)
11·8 
(7·5 to 
16·2)
–3·3 
(–9·8 to 
2·9)
1808 
(1102 to 
2971)
44·4 
(42·0 to 
47·0)
8·6 
(2·1 to 
14·8)
1 183 386 
(1 015 931 to 
1 372 615)
–3·2 
(–3·8 to 
–2·8)
–2·3 
(–2·5 to 
–2·0)
Oceania 11 953 
(10 254 to 
13 622)
–1·3 
(–3·4 to 
–0·7)
–2·0 
(–3·2 to 
1·5)
444 
(84 to 
1373)
22·1 
(6·4 to 
39·3)
–7·1 
(–29·7 to 
23·5)
40 
(8 to 
125)
48·5 
(30·5 to 
58·9)
4·9 
(–17·8 to 
35·4)
12 438 
(10 886 to 
14 063)
–0·9 
(–1·4 to 
–0·6)
–2·2 
(–2·6 to 
–1·7)
North Africa and 
Middle East
264 890 
(215 268 to 
327 017)
–2·6 
(–2·9 to 
–2·3)
–2·2 
(–2·6 to 
–1·8)
7721 
(4118 to 
14 403)
15·3 
(9·4 to 
21·1)
–1·2 
(–10·0 to 
7·4)
273 
(145 to 
508)
34·5 
(30·7 to 
38·0)
7·0 
(–1·8 to 
15·6)
272 884 
(221 272 to 
336 385)
–2·4 
(–2·7 to 
–2·1)
–2·1 
(–2·5 to 
–1·8)
South Asia 3 460 801 
(3 161 059 to 
3 815 348)
–1·7 
(–1·8 to 
–1·5)
–1·8 
(–1·9 to 
–1·6)
134 673 
(121 505 to 
149 109)
24·9 
(24·4 to 
25·4)
–1·5 
(–2·1 to 
–0·9)
3301 
(2978 to 
3654)
42·6 
(41·9 to 
43·2)
8·2 
(7·6 to 
8·8)
3 598 775 
(3 290 577 to 
3 966 147)
–1·4 
(–1·6 to 
–1·2)
–1·7 
(–1·9 to 
–1·6)
Sub-Saharan Africa 2 123 380 
(1 768 596 to 
2 579 273)
–0·9 (–1·4 
to 
–0·4)
–1·9 
(–2·4 to 
–1·4)
42 079 
(30 717 to 
57 455)
15·9 (13·8 
to 
18·0)
–2·2 
(–5·4 to 
1·1)
271 
(198 to 
371)
30·4 (28·4 
to 
32·5)
9·0 
(5·7 to 
12·2)
2 165 731 
(1 80 1974 to 
2 625 879)
–0·8 
(–1·3 to 
–0·2)
–1·9 
(–2·3 to 
–1·4)
Southern sub-Saharan 
Africa
378 324 
(290 890 to 
490 853)
0·9 
(–0·1 to 
1·9)
–1·0 
(–2·0 to 
–0·2)
9732 
(5716 to 
15 799)
13·9 
(10·1 to 
17·9)
–0·5 
(–4·8 to 
4·0)
63 
(37 to 
102)
34·4 
(31·2 to 
37·3)
10·6 
(6·4 to 
15·2)
388 119 
(299 438 to 
504 411)
1·1 
(0·0 to 
2·0)
–1·0 
(–2·0 to 
–0·2)
Western sub-Saharan 
Africa
545 758 
(444 535 to 
672 322)
–1·6 
(–2·3 to 
–1·0)
–2·9 
(–3·4 to 
–2·3)
13 358 
(7551 to 
22 859)
17·4 
(13·8 to 
21·1)
–3·9 
(–11·0 to 
3·3)
86 
(49 to 
147)
30·6 
(27·3 to 
34·0)
7·3 
(0·1 to 
14·4)
559 202 
(457 442 to 
686 867)
–1·5 
(–2·1 to 
–0·9)
–2·9 
(–3·4 to 
–2·3)
Eastern sub-Saharan 
Africa
809 654 
(678 742 to 
983 108)
–0·8 
(–1·2 to 
–0·3)
–1·5 
(–2·1 to 
–0·8)
16 166 
(10 561 to 
24 674)
21·8 
(17·9 to 
25·5)
–0·8 
(–4·9 to 
3·5)
104 
(68 to 
159)
29·4 
(27·1 to 
31·6)
10·3 
(6·2 to 
14·7)
825 924 
(693 500 to 
1 004 959)
–0·6 
(–1·1 to 
–0·2)
–1·5 
(–2·1 to 
–0·8)
Central sub-Saharan 
Africa
389 644 
(329 875 to 
455 126)
–0·9 
(–1·3 to 
–0·6)
–1·6 
(–2·0 to 
–1·1)
2824 
(1782 to 
4300)
8·6 
(5·5 to 
11·2)
–2·1 
(–6·2 to 
2·1)
18 
(11 to 
28)
28·1 
(25·3 to 
30·7)
9·0 
(4·9 to 
13·3)
392 486 
(332 258 to 
458 256)
–0·9 
(–1·2 to 
–0·6)
–1·6 
(–2·0 to 
–1·1)
Data in parentheses are 95% uncertainty intervals. Multidrug-resistant tuberculosis=multidrug-resistant tuberculosis without extensive drug resistance.
Table 1: Incident cases of tuberculosis, drug-susceptible tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis in HIV-negative individuals in 2016, 
and annualised rates of change of age-standardised incidence during the 1990–2006 and 2006–16 for 21 Global Burden of Disease regions for both sexes combined
For visualisation of data see 
http://vizhub.healthdata.org/
gbd-compare
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2006–16, which is a substantial change from the annualised 
increase of 9·2% (8·3–10·1) for 1990–2006 (appendix 
pp 88–100).
Globally from 2006 to 2016, the annualised rate of 
change in age­standardised incidence of multidrug­
resistant tuberculosis among HIV­negative individuals 
was –2·1% (95% UI –2·9 to –1·3; table 1), and the rate of 
change in mortality was –5·5% (–6·5 to –4·5; table 2). By 
contrast, we estimated that the burden of extensively 
drug­resistant tuberculosis has increased globally. From 
2006 to 2016, the annualised age­standardised rate of 
change in the incidence of extensively drug­resistant 
Drug-susceptible tuberculosis Multidrug-resistant tuberculosis Extensively drug-resistant 
tuberculosis
All HIV-negative tuberculosis
Number of 
deaths, 2016
Annualised rate of 
change of 
age-standardised 
mortality
Number of 
deaths, 
2016
Annualised rate of 
change of 
age-standardised 
mortality
Number 
of deaths, 
2016
Annualised rate of 
change of 
age-standardised 
mortality
Number of 
deaths, 2016
Annualised rate of 
change of 
age-standardised 
mortality
1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16
Global 1 105 898 
(1 055 638 to 
1 158 544)
–3·7 
(–4·3 to 
–3·4)
–4·4 
(–4·9 to 
–4·1)
96 238 
(79 994 to 
113 348)
11·9 
(10·9 to 
12·7)
–5·5 
(–6·5 to 
–4·5)
10 920 
(8896 to 
13 162)
43·9 
(42·7 to 
45·1)
3·1 
(1·8 to 
4·5)
1 213 057 
(1 161 548 to 
1 265 425)
–3·2 
(–3·7 to 
–2·9)
–4·5 
(–5·0 to 
–4·1)
High-income 12 759  
(11 633 to 
13 971)
–6·3 
(–6·6 to 
–5·9)
–3·5 
(–4·4 to 
–2·7)
457 
(347 to 
600)
–0·6 
(–1·8 to 
0·5)
–5·1  
(–7·2 to 
–2·7)
152 
(115 to 
202)
25·9 
(24·4 to 
27·3)
2·3 
(0·3 to 
4·7)
13 367 
(12 202 to 
14 591)
–6·1  
(–6·4 to 
–5·7)
–3·5  
(–4·4 to 
–2·7)
High-income 
North America
1041 
(991 to 
1095)
–7·0 
(–7·1 to 
–6·7)
–2·5 
(–2·9 to 
–2·0)
31 
(26 to 
38)
–8·7 
(–9·1 to 
–8·4)
–3·2 
(–3·7 to 
–2·6)
10 
(8 to 
13)
16·0 
(14·8 to 
17·3)
4·3 
(3·7 to 
4·8)
1082 
(1033 to 
1136)
–7·0 
(–7·2 to 
–6·8)
–2·5 
(–2·9 to 
–2·0)
Australasia 83 
(74 to 
93)
–5·0 
(–5·7 to 
–4·4)
–3·6 
(–4·8 to 
–2·4)
4 
(2 to 
8)
4·3 
(–3·9 to 
12·2)
–3·4 
(–13·7 to 
8·1)
1 
(1 to 
3)
19·1 
(12·1 to 
24·8)
4·1 
(–6·3 to 
15·6)
89 
(80 to 
99)
–4·7 
(–5·3 to 
–4·2)
–3·5 
(–4·4 to 
–2·5)
High-income Asia 
Pacific
7092 
(6222 to 
8028)
–7·1 
(–7·6 to 
–6·3)
–4·0 
(–5·5 to 
–2·5)
217 
(156 to 
304)
0·6 
(–1·4 to 
2·6)
–6·6 
(–9·7 to 
–3·4)
72 
(50 to 
102)
31·6 
(29·8 to 
33·4)
0·8 
(–2·2 to 
4·0)
7381 
(6469 to 
8328)
–6·9 
(–7·4 to 
–6·1)
–4·0 
(–5·6 to 
–2·6)
Western Europe 3428 
(3123 to 
3777)
–6·3 
(–6·6 to 
–6·0)
–4·4 
(–5·2 to 
–3·6)
154 
(121 to 
191)
–1·5 
(–2·5 to 
–0·5)
–4·6 
(–6·0 to 
–3·2)
51 
(40 to 
65)
23·7 
(22·4 to 
24·9)
2·9 
(1·5 to 
4·3)
3633 
(3322 to 
4005)
–6·1 
(–6·4 to 
–5·8)
–4·3 
(–5·1 to 
–3·5)
Southern Latin 
America
1116 
(955 to 
1273)
–6·1 
(–6·7 to 
–5·6)
–3·7 
(–5·2 to 
–2·3)
50 
(15 to 
141)
5·7 
(–2·2 to 
14·9)
–5·1 
(–16·6 to 
5·0)
17 
(5 to 
46)
32·6 
(27·9 to 
36·2)
2·4 
(–9·2 to 
12·4)
1183 
(1049 to 
1333)
–5·8 
(–6·3 to 
–5·3)
–3·7 
(–4·9 to 
–2·4)
Central Europe, 
eastern Europe, and 
central Asia
15 636  
(12 358 to 
19 998)
1·0  
(0·1 to 
1·7)
–7·8  
(–10·2 to 
–5·2)
6536 
(5013 to 
8358)
13·5 
(10·8 to 
16·6)
–8·2  
(–10·9 to 
–5·5)
3780  
(2873 to 
4801)
54·1 
(52·8 to 
55·1)
2·9 
(0·2 to 
5·6)
25 952  
(21 354 to 
31 882)
3·2  
(2·6 to 
3·8)
–6·9  
(–8·9 to 
–4·6)
Eastern Europe 10 165 
(7287 to 
14 072)
3·1 
(1·9 to 
4·1)
–8·1 
(–11·4 to 
–4·7)
4660 
(3317 to 
6321)
11·7 
(8·8 to 
15·1)
–7·4 
(–11·1 to 
–4·0)
2695 
(1893 to 
3686)
55·3 
(54·1 to 
56·6)
3·7 
(0·1 to 
7·1)
17 520 
(13 136 to 
23 086)
5·0 
(4·0 to 
5·9)
–6·8 
(–9·7 to 
–3·7)
Central Europe 2156 
(1944 to 
2435)
–4·2 
(–4·7 to 
–3·9)
–6·2 
(–7·4 to 
–5·0)
79 
(45 to 
135)
4·3 
(–1·6 to 
10·6)
–8·6 
(–16·2 to 
–1·5)
46 
(26 to 
80)
33·8 
(30·3 to 
37·2)
2·5 
(–5·1 to 
9·6)
2281 
(2075 to 
2569)
–4·0 
(–4·3 to 
–3·6)
–6·2 
(–7·2 to 
–5·0)
Central Asia 3315 
(2564 to 
4188)
–1·3 
(–2·8 to 
–0·1)
–8·3 
(–11·4 to 
–5·0)
1797 
(1330 to 
2282)
30·5 
(24·1 to 
37·6)
–10·6 
(–14·5 to 
–7·0)
1039 
(766 to 
1322)
58·7 
(56·9 to 
60·1)
0·5 
(–3·4 to 
4·1)
6150 
(5598 to 
6926)
2·4 
(1·8 to 
2·9)
–8·1 
(–9·2 to 
–6·8)
Latin America and 
Caribbean
15 076  
(14 239 to 
16 158)
–7·1 
(–7·5 to 
–6·7)
–4·5 
(–5·0 to 
–4·1)
865 
(693 to 
1085)
6·7  
(3·6 to 
10·3)
–6·6  
(–8·2 to 
–4·8)
180 
(140 to 
232)
34·8 
(33·3 to 
36·4)
3·1 
(1·4 to 
4·9)
16 121  
(15 263 to 
17 292)
–6·7  
(–7·1 to 
–6·3)
–4·6  
(–5·0 to 
–4·2)
Central Latin 
America
4988 
(4703 to 
5312)
–7·7 
(–8·0 to 
–7·5)
–4·4 
(–5·0 to 
–3·9)
277 
(219 to 
349)
13·5 
(11·8 to 
15·1)
–6·2 
(–7·9 to 
–4·5)
58 
(45 to 
74)
33·1 
(31·6 to 
34·6)
3·4 
(1·7 to 
5·1)
5323 
(5030 to 
5657)
–7·3 
(–7·6 to 
–7·0)
–4·5 
(–5·0 to 
–4·0)
Andean Latin 
America
2800 
(2299 to 
3434)
–9·8 
(–10·7 to 
–8·7)
–5·9 
(–7·4 to 
–4·3)
335 
(214 to 
504)
2·8 
(–1·3 to 
7·7)
–7·1 
(–10·9 to 
–3·3)
70 
(44 to 
107)
43·9 
(41·6 to 
46·4)
2·5 
(–1·3 to 
6·3)
3205 
(2723 to 
3929)
–9·1 
(–9·9 to 
–7·9)
–5·9 
(–7·3 to 
–4·5)
Caribbean 1890 
(1490 to 
2306)
–5·5 
(–6·4 to 
–4·3)
–3·1 
(–4·4 to 
–1·7)
28 
(7 to 
86)
0·4 
(–8·7 to 
10·0)
–7·4 
(–18·1 to 
4·1)
6 
(2 to 
18)
28·9 
(21·5 to 
35·5)
2·2 
(–8·5 to 
13·7)
1923 
(1522 to 
2335)
–5·4 
(–6·3 to 
–4·2)
–3·1 
(–4·4 to 
–1·8)
Tropical Latin 
America
5315 
(5065 to 
5662)
–4·4 
(–4·7 to 
–4·1)
–4·3 
(–4·8 to 
–3·8)
224 
(189 to 
263)
19·9 
(19·3 to 
20·5)
–6·1 
(–6·9 to 
–5·3)
47 
(39 to 
56)
31·8 
(30·5 to 
33·0)
3·5 
(2·7 to 
4·3)
5586 
(5330 to 
5940)
–4·1 
(–4·3 to 
–3·8)
–4·4 
(–4·8 to 
–3·9)
(Table 2 continues on next page)
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tuberculosis was 7·9% (6·6–9·1; table 1), and the rate of 
change for mortality was 3·1% (1·8–4·5; table 2). For the 
same time period, the annualised age­standardised rates 
of change for multidrug­resistant tuberculosis among 
HIV­positive individuals was –4·6% (–6·6 to –2·7) 
for incidence and –9·1% (–11·2 to –7·2) for mortality. 
For extensively drug­resistant tuberculosis among 
HIV­positive in dividuals, the annualised rate of change 
was 7·2% (5·4 to 8·7) for incidence and 2·3% (0·9 to 
3·7) for mortality (appendix pp 75–100).
Region-specific and country-specific tuberculosis 
incidence and mortality
Although we observed a global decrease in the burden of 
tuberculosis, this trend was not uniform across all 
regions and countries. During 2006–16, among HIV­
negative individuals the annual percentage change in the 
incidence of tuberculosis varied from –6·2% (95% UI 
–6·7 to –5·6) in Kazakhstan, to 1·2% (0·7–1·8) in the 
Philippines, and 1·3% (0·6–2·1) in Uruguay (appendix 
pp 48–61). In 2016, the age­standardised incidence rate 
(per 100 000 population) of tuberculosis in HIV­negative 
individuals varied from 3·1 (2·8–3·4) in the USA and 
3·8 (2·5–5·4) in Palestine, to 729·6 (537·3–1013·1) in 
Lesotho and 842·7 (670·9–1040·0) in Central African 
Republic (figure 3; appendix pp 101–07).
Age­standardised rates of tuberculosis mortality among 
HIV­negative individuals decreased at varying rates across 
countries and territories from 2006 to 2016, with the 
highest annual decreases seen in Kazakhstan (–13·7% 
Drug-susceptible tuberculosis Multidrug-resistant tuberculosis Extensively drug-resistant 
tuberculosis
All HIV-negative tuberculosis
Number of 
deaths, 2016
Annualised rate of 
change of 
age-standardised 
mortality
Number of 
deaths, 
2016
Annualised rate of 
change of 
age-standardised 
mortality
Number 
of deaths, 
2016
Annualised rate of 
change of 
age-standardised 
mortality
Number of 
deaths, 2016
Annualised rate of 
change of 
age-standardised 
mortality
1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16 1990–2006 2006–16
(Continued from previous page)
Southeast Asia, east 
Asia, and Oceania
194 147  
(183 457 to 
205 231)
–6·1  
(–6·7 to 
–5·6)
–6·4  
(–7·0 to 
–5·7)
11 293  
(8191 to 
15 536)
3·3  
(1·5 to 
5·1)
–9·5  
(–12·9 to 
–5·9)
2720  
(1951 to 
3788)
43·7  
(41·8 to 
45·5)
2·3  
(–1·2 to 
5·8)
208 159  
(198 135 to 
219 944)
–5·7  
(–6·3 to 
–5·3)
–6·5  
(–7·1 to 
–6·0)
East Asia 38 192 
(35 902 to 
42 306)
–8·5 
(–9·0 to 
–8·1)
–8·3 
(–8·9 to 
–7·4)
4297 
(3483 to 
5259)
–0·2 
(–1·1 to 
0·8)
–11·3 
(–12·6 to 
–10·0)
1035 
(822 to 
1293)
40·4 
(38·9 to 
41·8)
0·5 
(–0·8 to 
1·8)
43 523 
(41 277 to 
48 120)
–7·8 
(–8·2 to 
–7·4)
–8·5 
(–9·1 to 
–7·6)
Southeast Asia 155 084 
(145 733 to 
165 219)
–5·1 
(–5·8 to 
–4·5)
–5·9 
(–6·6 to 
–5·1)
6938 
(4218 to 
10 905)
9·1 
(4·4 to 
14·0)
–8·1 
(–13·9 to 
–2·3)
1671 
(1012 to 
2659)
48·7 
(46·0 to 
51·4)
3·6 
(–2·1 to 
9·5)
163 693 
(154 881 to 
173 618)
–4·8 
(–5·5 to 
–4·1)
–5·9 
(–6·6 to 
–5·2)
Oceania 573 
(457 to 
678)
–3·4 
(–6·1 to 
–2·2)
–4·1 
(–6·7 to 
0·4)
44 
(10 to 
119)
16·9 
(1·4 to 
33·3)
–8·6 
(–28·3 to 
18·6)
11 
(2 to 
29)
44·2 
(27·9 to 
52·5)
3·2 
(–16·5 to 
30·3)
628 
(547 to 
721)
–2·7 
(–3·6 to 
–1·9)
–4·4 
(–5·6 to 
–3·4)
North Africa and 
Middle East
35 401 
(23 520 to 
52 168)
–4·4 
(–5·1 to 
–3·7)
–4·7 
(–6·0 to 
–3·5)
3392 
(1305 to 
7231)
16·5 
(10·7 to 
22·3)
–4·8 
(–14·9 to 
4·8)
316 
(121 to 
684)
39·8 
(33·8 to 
44·1)
3·2 
(–6·9 to 
12·8)
39 109 
(25 473 to 
57 682)
–3·9 
(–4·4 to 
–3·3)
–4·7 
(–5·3 to 
–3·9)
South Asia 451 816 
(420 616 to 
480 353)
–4·7 
(–5·2 to 
–4·3)
–4·9 
(–5·6 to 
–4·3)
52 768 
(43 568 to 
62 706)
22·0 
(21·3 to 
22·7)
–5·0 
(–5·9 to 
–4·2)
3416 
(2777 to 
4170)
46·8 
(45·5 to 
48·2)
4·5 
(3·6 to 
5·4)
508 000 
(474 024 to 
538 330)
–4·0 
(–4·5 to 
–3·6)
–4·9 
(–5·6 to 
–4·2)
Sub-Saharan Africa 381 032  
(353 681 to 
415 691)
–1·3  
(–2·2 to 
–0·5)
–3·8  
(–4·4 to 
–3·3)
20 924  
(15 874 to 
27 461)
16·1  
(14·1 to 
18·1)
–4·5  
(–7·1 to 
–1·8)
357  
(269 to 
473)
37·3  
(35·6 to 
38·9)
6·7  
(4·1 to 
9·3)
402 312  
(374 030 to 
438 809)
–1·0  
(–1·8 to 
–0·2)
–3·8  
(–4·4 to 
–3·4)
Southern sub-
Saharan Africa
35 286 
(31 658 to 
38 511)
2·9 
(0·1 to 
4·0)
–5·7 
(–6·8 to 
–4·0)
2604 
(1717 to 
4034)
15·7 
(11·6 to 
19·7)
–5·6 
(–9·6 to 
–1·1)
44 
(29 to 
68)
38·2 
(35·6 to 
40·9)
5·6 
(1·6 to 
10·1)
37 935 
(34 180 to 
41 177)
3·3 
(0·5 to 
4·3)
–5·7 
(–6·8 to 
–4·1)
Western sub-
Saharan Africa
85 821 
(75 972 to 
100 174)
–2·8 
(–3·5 to 
–2·1)
–4·4 
(–5·6 to 
–3·3)
5677 
(3510 to 
8928)
15·7 
(12·5 to 
19·0)
–6·4 
(–12·2 to 
–0·5)
97 
(59 to 
154)
36·7 
(33·8 to 
39·5)
4·8 
(–1·0 to 
10·7)
91 594 
(80 902 to 
106 901)
–2·3 
(–3·0 to 
–1·7)
–4·6 
(–5·6 to 
–3·5)
Eastern sub-
Saharan Africa
164 799 
(147 918 to 
184 516)
–1·7 
(–2·8 to 
0·2)
–3·7 
(–4·5 to 
–3·0)
10 563 
(7041 to 
15 603)
21·2 
(16·6 to 
25·6)
–3·0 
(–6·9 to 
0·9)
180 
(118 to 
268)
38·0 
(35·9 to 
40·0)
8·1 
(4·2 to 
12·0)
175 543 
(157 583 to 
196 713)
–1·3 
(–2·4 to 
0·6)
–3·6 
(–4·4 to 
–3·0)
Central sub-
Saharan Africa
95 003 
(75 102 to 
114 664)
–0·6 
(–1·8 to 
0·7)
–2·9 
(–3·8 to 
–2·1)
2072 
(1209 to 
3262)
8·7 
(5·5 to 
11·9)
–3·5 
(–7·4 to 
0·7)
35 
(21 to 
56)
36·1 
(32·8 to 
39·3)
7·7 
(3·8 to 
11·8)
97 110 
(76 824 to 
117 021)
–0·4 
(–1·6 to 
0·8)
–3·0 
(–3·8 to 
–2·1)
Data in parentheses are 95% uncertainty intervals. Multidrug-resistant tuberculosis=multidrug-resistant tuberculosis without extensive drug resistance.
Table 2: Mortality from tuberculosis for drug-susceptible tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis in HIV-negative individuals in 2016, 
and annualised rates of change of age-standardised mortality during the periods 1990–2006 and 2006–16 for 21 Global Burden of Disease regions for both sexes
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[95% UI –16·2 to –11·3]), Estonia (–9·4% [–11·8 to –7·1]), 
Kuwait (–9·0% [–12·1 to –6·2]), China (–8·8% [–9·5 to 
–7·9]), and Myanmar (–8·8% [–10·4 to –7·0]; appendix 
pp 62–74). Among HIV­negative individuals in 2016, age­
standardised mortality rates (per 100 000 population) of 
tuberculosis were the highest (ie, >150 deaths per 
100 000 population) in Burundi, Central African Republic, 
Democratic Republic of the Congo, Lesotho, Somalia, and 
Zambia (figure 3). The co­ rresponding age­standardised 
incidence and mortality rates of tuberculosis among HIV­
positive individuals, by country and with annual 
percentage changes, are in the appendix (pp 47, 75–100).
Trends in the annualised rate of change in age­
standardised incidence and mortality for multidrug­
resistant tuberculosis varied largely across countries, 
with no consistent pattern worldwide for HIV­negative 
(appendix pp 48–74) or for HIV­positive individuals 
(pp 75, 88). Among HIV­negative individuals, Kyrgyzstan, 
Lesotho, Namibia, Somalia, Swaziland (eSwatini), and 
Turkmenistan had the highest age­standardised inci­
dence of multidrug­resistant tuberculosis (ie, >20 per 
100 000 population) in 2016, whereas age­standardised 
mortality for multidrug­resistant tuberculosis was highest 
(ie, >15 per 100 000 population) in Somalia, Lesotho, 
eSwatini, and Afghanistan in the same year (appendix pp 
108–14). More detailed results for HIV­negative individuals 
broken down by age, sex, and year, and data for HIV­
positive individuals, are available online.
Observed versus expected tuberculosis burden
In 2016, among HIV­negative individuals, several regions 
(eg, eastern Europe, central Asia, southeast Asia, 
south Asia, and sub­Saharan Africa) had higher than 
expected (on the basis of SDI) age­standardised incidence 
and mortality of drug­susceptible tuberculosis (figure 4). 
At the regional level, the highest observed­to­expected 
ratios were in southern sub­Saharan Africa (13·7 for 
incidence and 14·9 for mortality), and the lowest ratios 
were in high­income North America (0·4 for incidence) 
and Oceania (0·3 for mortality). For multidrug­resistant 
tuberculosis, eastern Europe had the highest observed­to­
expected ratios for incidence (67·3) and mortality (73·0), 
and high­income North America had the lowest ratios 
(0·4 for incidence and 0·5 for mortality). We found no 
association between SDI and incidence of or mortality 
due to extensively drug­resistant tuberculosis (data not 
shown).
In 2016, among HIV­negative individuals, observed­to­
expected ratios were greater than two for incidence 
of drug­susceptible tuberculosis in 54 countries, for 
drug­susceptible tuberculosis mortality in 38 countries, 
for incidence of multidrug­resistant tuberculosis in 
83  countries, and for multidrug­resistant tuberculosis 
mortality in 96 countries (figure 4). These countries were 
located mainly in sub­Saharan Africa and southeast Asia. 
For HIV­positive individuals in 2016, observed­to­expected 
ratios were greater than two in 138 countries for inci­
dence of drug­susceptible tuberculosis, 82 countries for 
drug­susceptible tuberculosis mortality, 105 countries 
for incidence of multidrug­resistant tuberculosis, and 
95 countries for multidrug­resistant tuberculosis mortality. 
Most of these countries were in sub­Saharan Africa and 
eastern Europe. Across tuberculosis drug­resistance types 
and by HIV­status, the highest observed­to­expected ratios 
were 17·9 for the incidence of drug­susceptible tuberculosis 
in South Africa to 3188·6 for the incidence of multidrug­
resistant HIV­tuberculosis in eSwatini.
Discussion
This study provides a comprehensive assessment of 
levels and trends in the burden of tuberculosis by drug­
resistance type and HIV status for 195 countries and 
territories over the past 27 years. Despite the fact that 
HIV and drug­resistant tuberculosis have emerged as 
big challenges to tuberculosis control efforts, most 
incident cases of tuberculosis and deaths due to 
tuberculosis in 2016 occurred in HIV­negative in­
dividuals who were susceptible to first­line tuberculosis 
drugs. More than half of these cases and deaths occ­
urred in south and southeast Asia. HIV­tuberculosis 
Figure 2: Global age-sex distribution of incident cases of tuberculosis (A) and deaths due to tuberculosis (B) 
among HIV-negative individuals in 2016
Error bars are 95% uncertainty intervals.
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Figure 3: Age-standardised tuberculosis incidence (A) and mortality (B) in HIV-negative individuals, 2016
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. Isl=Islands. FSM=Federated States of Micronesia. TLS=Timor-Leste.
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(Figure 4 continues on next page)
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comprises 13% (1·40 million of 10·42 million) of in­
cident cases of tuberculosis and 16% (0·24 million of 
1·45 million) of deaths due to tuberculosis, most of 
which occurred in sub­Saharan Africa. Over the past 
decade, the global rate of decrease in the incidence 
of tuberculosis is about a third for HIV­negative 
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(Figure 4 continues on next page)
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individuals, and a half for HIV­positive in dividuals, 
compared with the rate of decrease in tuber culosis 
mortality, with substantial variations between countries. 
Trends in multidrug­resistant tuberculosis also vary 
largely across countries, with no consistent pattern 
worldwide. Several regions had a higher burden of 
tuberculosis than expected given their level of socio­
demographic development in 2016.
We estimated that the incidence of tuberculosis 
among HIV­negative individuals has decreased by only 
1·3% (95% UI 1·2–1·5) annually during 2006–16. This rate 
is much lower than the 10% or more annual reduction 
needed by 2025 to reach the SDG target to end the 
tuberculosis epidemic by 2030.3 We identified the countries 
with the fastest and slowest improvements in tuberculosis 
incidence during 2006–16. The fastest annual decrease 
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Figure 4: Ratio of observed to expected age-standardised incidence and mortality on the basis of SDI by GBD region and country in 2016, for drug-susceptible 
tuberculosis and multidrug-resistant tuberculosis, by HIV status
Ratio of observed age-standardised incidence or mortality to that expected on the basis of a country’s SDI for a given year. A ratio of one means that observed and 
expected values are equal. A ratio higher than one means the observed rate is greater than expected, and a ratio of less than one means the observed rate is lower 
than expected. GBD=Global Burden of Disease. Multidrug-resistant tuberculosis=multidrug-resistant tuberculosis without extensive drug resistance. 
SDI=Socio-demographic Index.
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in incidence was observed in Kazakhstan, where im­ 
provements were attributable to advances in diagnostics 
and effective treatment of newly diagnosed tuberculosis 
cases.23 We saw little to no improvement in some countries, 
including the Philippines and Uruguay. In the Philippines, 
a high proportion of smear­negative individuals who are 
positive for tuberculosis by Xpert MTB/RIF assay (Cepheid, 
USA) has been documented in high­risk populations, 
including prison inmates and indigenous populations, 
suggesting that sputum­smear microscopy alone as a 
routine diagnostic test is inadequate.24 In Uruguay, a 
decrease in treatment success rate for new cases of 
tuberculosis (from 84% in 2010 to 77% in 2015)25 probably 
contributes to the country’s the lack of progress.
Despite improvements in socio­demographic conditions, 
several regions have fallen behind in their progress to 
reduce the burden of tuberculosis. In 2016, most countries 
in Asia, sub­Saharan Africa, and eastern Europe had a 
higher burden of tuberculosis (both drug susceptible and 
multidrug resistant) than expected given their level of 
socio­demographic development. In many countries, 
providing treatment services for multidrug­resistant 
tuberculosis remains a challenge, partly because of the 
high cost of second­line drugs and poor adherence to 
regimens.26,27 Globally in 2016, only 22% of people 
with newly diagnosed drug­resistant tuberculosis were 
estimated to begin treatment, with a treatment success 
rate of 54%.28 Evidence suggests that alcohol abuse and 
HIV infection are associated with increased risk of 
unsuccessful outcomes in patients with multidrug­
resistant tuberculosis, but the association is unclear for 
other factors and comorbidities such as smoking and 
chronic kidney disease.29 A more comprehensive under­
standing of the key drivers of unsuccessful treatment 
outcomes in these patients is crucial to improving their 
treatment outcomes.
Although the burden of tuberculosis remains far off 
from the expected level in many countries with a high 
burden of tuberculosis, the prevalence of diabetes—an 
important risk factor for both tuberculosis and adverse 
outcomes from tuberculosis treatment—has increased 
over time worldwide as a consequence of several factors 
including population ageing and exposure to lifestyle­
related risk factors,11,30 creating additional challenges 
for tuberculosis care and prevention. Because of the 
interaction of tuberculosis with diabetes and HIV/AIDS, 
integrating control programmes for the three diseases 
could help prevent tuberculosis among people with 
HIV/AIDS and diabetes and reduce the burden of all 
three diseases.31 Additionally, efforts to prevent other risk 
factors for tuberculosis, including smoking and alcohol 
misuse, could have a complementary effect on the burden 
of tuberculosis.2
In countries with a higher burden of tuberculosis than 
expected on the basis of SDI, an important first step is to 
identify the reasons for falling behind so that appropriate 
measures can be taken. Gaps in case detection and delays 
in diagnosis and treatment most likely contribute to the 
burden being higher than expected, and country­specific 
reasons should also be investigated. Although national 
tuberculosis programmes were notified of about 
6·3 million new or relapsed cases of tuberculosis globally 
in 2016,28 we estimated that the number of incident cases 
in 2016 was 10·4 million, implying a global case detection 
rate of 61%. Evidence suggests that a routine passive case­
finding strategy is insufficient for detecting all tuberculosis 
cases.32,33 Active case finding has been recommended as a 
complementary strategy to passive case finding to increase 
case detection; nevertheless, the effect of active case 
finding on treatment outcomes and rate of transmission, 
and longer­term effects on the epidemiology of 
tuberculosis, have yet to be determined.32
Also, despite advances in tuberculosis diagnostics, 
smear microscopy remains the most commonly used 
diagnostic test in many countries that are endemic for 
tuberculosis.34 The Xpert MTB/RIF assay has higher 
sensitivity for the detection of tuberculosis than smear 
microscopy,35 but few countries use Xpert for general 
tuberculosis case finding.36 Policies on the use of Xpert 
MTB/RIF vary largely between countries, with only 
a subset of patients with tuberculosis being eligible for 
the test (eg, patients with suspected drug resistance, 
HIV­positive individuals).36 A scale­up of Xpert MTB/RIF 
could help in detecting additional cases, but it has been 
impeded by several factors, including high costs, reliance 
on funding from international donors, and the lack of 
subsidised pricing in the private sector, which is relied 
on for most tuberculosis cases in some countries.26
Overall, even with differences in methods used, both 
GBD 2016 and WHO estimated 10·4 million incident 
cases of tuberculosis in 2016, although our estimated 
number of all tuberculosis deaths (1·45 million) is lower 
than WHO’s estimate (1·7 million) for 2016.28 The 
20 countries with the highest burden, as assessed by the 
number of incident cases, differ between our estimates 
and WHO’s: WHO includes Angola, Brazil, and Thailand; 
instead, we include Uganda, Zambia, and Zimbabwe. The 
most notable difference between our and WHO’s estimates 
is between the estimated numbers of tuberculosis deaths 
among children. We estimated 39 311 deaths (95% UI 
34 415–44 847) among children who are HIV negative and 
younger than 15 years for 2016, which is substantially 
lower than the estimates from WHO (201 000 deaths)28 and 
Dodd and colleagues (200 000 deaths).37 The input data and 
the methods used to generate estimates of deaths in 
children due to tuberculosis are very different between 
studies: we used vital registration and verbal autopsy data 
and the CODEm strategy to estimate tuberculosis deaths 
in children and WHO used the method of Dodd and 
colleagues from their 2017 study37 in which child mortality 
due to tuberculosis was back­calculated from the incidence 
and case­fatality ratio. WHO estimated the incidence 
of tuber culosis in children by combining results 
from two app roaches: the case detection rate adjustment 
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approach (ie, incidence=notifications/estimated case 
detection rate); and the method of Dodd and colleagues 
from their 2014 study38 in which incidence was estimated 
from the annual risk of infection in children, WHO adult 
smear­positive tuberculosis prevalence data, and 
demographic informa tion by use of a mathematical model. 
Both our method and the method used by WHO and Dodd 
and colleagues have limitations. Specifically, concerns 
have been raised about the misclassification of tuberculosis 
deaths in children as deaths due to pneumonia in countries 
with a high burden of tuberculosis.39 In this study, we did 
not redistribute pneumonia deaths to tuberculosis deaths 
because of a lack of evidence on whether tuberculosis is a 
cause or comorbidity of acute severe pneumonia in 
children.40 The back­calculation approach used by WHO 
and Dodd and colleagues most likely has substantial 
uncertainty due to assumptions in the process of 
estimating annual risk of infection, the prevalence of adult 
tuberculosis, and case detection rates.
Our study has several limitations. First, our assessment 
of the trends in the burden of multidrug­resistant 
tuberculosis was restricted by a paucity of time­series data 
for many countries in Asia and Africa. We assumed that 
these countries have a similar age­sex distribution of 
multidrug­resistant tuberculosis to other countries in the 
same region and used this common distribution to 
generate trend estimates for countries and years with little 
data; the lack of data in a particular country is reflected in 
wide uncertainty intervals. Second, verbal autopsy studies 
have modest sensitivity in identifying tuberculosis 
deaths.41–43 However, at the typical range of the cause 
fraction of deaths due to tuberculosis in India and 
sub­Saharan Africa (3–5%),43 and at the reported level of 
sensitivity and specificity of attributing tuberculosis as the 
cause of death in a large, multicentre, verbal autopsy 
validation study,43 we estimate that the false positives and 
false negatives largely cancel out. Third, as noted in our 
previous publication,2 the main challenge in our statistical 
triangulation approach has been the shortage of data from 
surveys on cause of death and prevalence, particularly 
from countries in sub­Saharan Africa with a high 
prevalence of HIV. We applied sophisticated modelling 
methods and covariates, using distributions across geo­
graphies and time to help predict for those locations. 
Accordingly, the estimates for a location with sparse data 
are coupled with wider uncertainty intervals. Fourth, to 
inform the case­fatality ratio among patients with 
untreated tuberculosis for our mortality­to­incidence ratio 
regression, we used data from a single community­based 
follow­up study done in Bangalore, India;21 two other 
community­based studies,44 done in India45 and the USA, 46,47 
were not included because of a lack of information about 
the treatment of tuberculosis or any systematic follow­up 
of cases.
Despite these limitations, we made several improve­
ments in our methods compared with GBD 2015. First, 
we no longer used case­detection rates based on expert 
opinion in the process of estimating the incidence of 
tuberculosis. Instead, we used a mortality­to­incidence 
ratio approach to better reflect higher mortality and 
incidence in low­income and middle­income countries. 
Second, we strengthened our statistical triangulation 
approach by incorporating population­based surveys of 
latent tuberculosis infection, and modelling incidence, 
prevalence, and mortality simultan eously among the 
population who are latently infected to enhance 
comparability across countries. Because we used 
Bayesian meta­regression to generate an incidence 
estimate that is consistent with prevalence data or cause­
specific mortality estimates, our estimated incidence 
might differ from countries’ official statistics (even from 
those with a four star or five star quality ratings). Third, 
we improved our estimates of tuber culosis mortality by 
including additional covariates that have proximal or 
strong associations with tuberculosis mortality (ie, 
prevalence of latent tuber culosis infection, prevalence of 
active tuberculosis disease, proportion of adults who are 
underweight, and HAQ Index). These improvements, 
together with substantial efforts to collate data for the 
estimation of tuberculosis burden, have resulted in 
changes in GBD 2016 compared with GBD 2015, 
especially in estimates of mortality. The global number of 
deaths in 2016 due to tuberculosis was 11% higher than 
the GBD 2015 estimate for 2015. The increase mainly 
occurred in some African countries—notably, Burundi, 
Central African Republic, Congo, Democratic Republic 
of the Congo, Gabon, Nigeria, Uganda, and Zambia had 
more than twice the number of estimated deaths in 2016 
compared with in 2015. Fourth, in GBD 2015, we did 
not separately examine the burden of multidrug­
resistant tuberculosis. Given their epidemiological and 
clinical importance, we included estimates of multidrug­
resistant and extensively drug­resistant tuberculosis in 
GBD 2016. Further estim ation and mapping of the 
burden of tuberculosis by drug­resistance type and 
HIV status at a finer spatial resolution could better 
inform surveillance and the targeting of resources for 
interventions.48
As countries work towards achieving the SDG target 
to end the tuberculosis epidemic by 2030, contemporary 
information on the levels and trends of the burden of 
tuberculosis is essential to track and monitor the 
progress of control efforts in individual countries. 
Locations with the greatest improvements in controlling 
tuberculosis could provide insight into successful 
programmatic strategies for countries with stagnant 
progress. Our findings suggest that, if current trends in 
tuberculosis incidence continue, few countries will 
meet the SDG target. Progress needs to be accelerated 
by improving the quality of and access to tuberculosis 
diagnosis and care, scaling up of interventions to 
prevent risk factors for tuberculosis, and integrating 
control programmes for tuberculosis, HIV, and 
diabetes.
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